CyteGen
Stage
Unattributed | AliveTotal Raised
$2.45MLast Raised
$1.1M | 2 yrs agoAbout CyteGen
CyteGen is a medical company that aims to extend people's lives by correcting age-related sickness and pain in the body. The business has discovered chemicals that promote the elimination of defective mitochondria while promoting the creation of new, healthy mitochondria, allowing doctors to use genomes, proteomics, and biochemical data to optimize cellular metabolism.
Loading...
Loading...
CyteGen Patents
CyteGen has filed 2 patents.
The 3 most popular patent topics include:
- ageing
- chronic fatigue syndrome
- gerontology

Application Date | Grant Date | Title | Related Topics | Status |
---|---|---|---|---|
7/22/2016 | Transcription factors, Cell biology, Ageing, Cell signaling, Clusters of differentiation | Application |
Application Date | 7/22/2016 |
---|---|
Grant Date | |
Title | |
Related Topics | Transcription factors, Cell biology, Ageing, Cell signaling, Clusters of differentiation |
Status | Application |
Latest CyteGen News
Jan 13, 2022
By Share The accelerator building on the UWM Innovation Campus in Wauwatosa. Wauwatosa-based CyteGen has raised another $1.1 million to fund their research into extending human life and reversing age-related decline. A Jan. 13 SEC filing shows the company raised the $1.1 million in equity through three… Want to Read More? Paid BizTimes subscribers get unlimited access to all Insider content and much more. Learn more in our Insider FAQ . Wauwatosa-based CyteGen has raised another $1.1 million to fund their research into extending human life and reversing age-related decline. A Jan. 13 SEC filing shows the company raised the $1.1 million in equity through three investors. This is their second funding round. The company also raised $1 million back in April of 2018. CyteGen Corp. was co-founded in 2015 by Nuray George Ugras and is based in the UWM Innovation accelerator at 1225 Discovery Parkway in Wauwatosa. The company is focused on mitochondrial dysfunction’s link to aging and neurodegenerative disorders such as Parkinson’s and Alzheimer’s.CyteGen’s team includes experts and researchers from the Medical College of Wisconsin, the University of Wisconsin-Madison, Johns Hopkins University, the University of California-San Francisco Parnassus Campus, biopharma company GlaxoSmithKline, MIT and more.CyteGen was also awarded $252,092 in September of 2020 though a Small Business Technology Transfer (STTR) grant. The company was listed as still being in Phase 1, which means they are still in the concept development phase.According to award information found on the STTR website, CyteGen was seeking funding to test the hypothesis that “endurance exercise stimulates the release of circulating factors that improve mitochondrial fitness.” CyteGen’s goal is to identify these endogenous factors and engineer them to treat diseases in which mitochondrial dysfunction. Sign Up Now Sign up for BizTimes Daily Alerts Stay up-to-date on the people, companies and issues that impact business in Milwaukee and Southeast Wisconsin
CyteGen Frequently Asked Questions (FAQ)
Where is CyteGen's headquarters?
CyteGen's headquarters is located at 4230 N. Oakland Avenue, Milwaukee.
What is CyteGen's latest funding round?
CyteGen's latest funding round is Unattributed.
How much did CyteGen raise?
CyteGen raised a total of $2.45M.
Who are the investors of CyteGen?
Investors of CyteGen include Breakout Labs.
Loading...
Loading...